Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure

Stifel maintained its Buy rating and $50 price target on NewAmsterdam Pharma despite Novartis's HORIZON trial failing to meet endpoints, an event linked to NAMS's recent share weakness; the stock trades at $25.40, down 27.6% year-to-date. Stifel argues the read-through to NewAmsterdam's obicetrapib PREVAIL trial is nuanced, citing different baseline Lp(a), LDL-C and event-rate dynamics, while PREVAIL has shown nearly 20% LDL-C reduction. PREVAIL's interim readout is expected in Q1 2027, while Novartis Phase III HORIZON data anticipated in July or August remains a near-term catalyst for validation of Lp(a) biology.

Analysis

The usable signal is not the broker target but a potentially adverse update to cardiovascular outcomes-biology sentiment. If the negative result is confirmed, NAMS risks further multiple compression because obicetrapib’s premium valuation depends on translating lipid changes into outcomes, not simply demonstrating LDL-C lowering. The cited subgroup analogy is hypothesis-generating rather than a substitute for a contemporaneous outcomes result; that leaves NAMS exposed to a long duration-risk period before its own definitive catalyst.

There is also a material data-quality issue: the item contains internally inconsistent timing and characterization of the referenced HORIZON program. Do not underwrite a position from this report without confirming the sponsor’s primary release, endpoint definition, hazard ratio, subgroup hierarchy, and whether the event applies to the relevant mechanism. A confirmed failure driven by low event rates or population selection would be less damaging to NAMS than a clean mechanistic null, but the market may initially price both outcomes similarly.

Over the next days, NVS can face modest sentiment pressure around its cardiovascular pipeline, while NAMS has asymmetric downside because its nearer valuation anchor is external read-through rather than cash-flow fundamentals. Over 1-3 months, the critical catalyst is a verified detailed-data presentation and subsequent analyst model revisions; over 6-18 months, financing/runway and enrollment/event-rate updates matter more than lipid biomarker data. The contrarian setup is that an indiscriminate NAMS selloff could become attractive only if detailed data isolate failure to trial design and NAMS maintains a credible path to a statistically powered outcomes readout.

Falsify the cautious view with independently verified evidence that the external program met clinically meaningful outcomes in a comparable population, or with NAMS reporting event accrual and cash runway sufficient to reach its key readout without dilutive financing. Conversely, a guidance cut, extended endpoint timeline, or capital raise before the next major data catalyst would validate a lower valuation framework.

Key Decisions for Investors

• No immediate directional NAMS position until the primary trial disclosure is reconciled with the article’s conflicting claims; create an event alert for the sponsor release, detailed endpoint table, and NAMS management commentary.
• If verified detailed data show a broad mechanistic outcomes failure, short NAMS tactically versus long XBI for a 1-3 month catalyst window; size small given biotech borrow/short-squeeze risk, and cover if NAMS recovers above the pre-data trading range on credible differentiation evidence.
• If detailed data instead attribute failure to low event rates or non-comparable enrollment and NAMS confirms adequate cash through its next major readout, consider a staged long NAMS only after volatility normalizes; target a 2:1 upside/downside structure with a stop on financing or timeline deterioration.
• Avoid treating NVS as a clean hedge for NAMS: its diversified earnings base dilutes pipeline sensitivity. Use NVS only as a sentiment-monitoring proxy, with any short exposure contingent on confirmed pipeline impairment rather than the initial headline.